 VICTORIA, British Columbia ROCKVILLE, Md.--BUSINESS WIRE--Aurinia Pharmaceuticals Inc. NASDAQ: AUPH TSX: AUP Aurinia or the Company today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNISTM voclosporin in lupus nephritis LN. The data were shared at the National Kidney Foundation NKF 2021 Spring Clinical Meetings by Anca D. Askanase, M.D., M.P.H., Founder and Director of Columbia University Irving Medical Centers Lupus Center and the Dire 